Stelara® (ustekinumab) five-year results presented from long-term extension study of clinical response and remission in patients with moderate to severe crohn’s disease

The janssen pharmaceutical companies of johnson & johnson today announced new, final five-year data from the phase 3 im-uniti open-label, long-ter

AREC Ratings Summary

AREC Quant Ranking